CTIM-09. PHASE 1/1B TRIAL OF FC-ENGINEERED ANTI-CD40 AGONIST MONOCLONAL ANTIBODY (2141-V11) INFUSED WITH D2C7-IT IN ENHANCING DISEASE BY CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (RMG)
CTIM-09. 1/1b 期试验,评估 FC 工程化抗 CD40 激动剂单克隆抗体 (2141-V11) 与 D2C7-IT 联合输注治疗复发性恶性胶质瘤 (RMG) 的疗效,采用对流增强递送 (CED) 技术。
期刊:Nucleic Acids Research
影响因子:13.1
doi:10.1093/nar/gkad866
Hou, Qian; Chatterjee, Surajit; Lund, Paul E; Suddala, Krishna C; Walter, Nils G; Desjardins, Annick; Chandramohan, Vidya; Landi, Daniel; Peters, Katherine; Johnson, Margaret O; Low, Justin; Khasraw, Mustafa; Threatt, Stevie; Bullock, Chevelle; Herndon, James; Lipp, Eric; Friedman, Allan; Friedman, Henry; Ashley, David; Osorio, Juan; Ravetch, Jeffrey; Bigner, Darell